Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
drugs
fda
3
×
life sciences
national blog main
alnylam pharmaceuticals
boston
boston blog main
boston top stories
patisiran
rna interference
san francisco blog main
san francisco top stories
acute hepatic porphyrias
akcea therapeutics
akin akinc
aminolevulinic acid
barry greene
biotech
boston university
cannabidiol
dan ollendorf
dravet syndrome
epidiolex
fen-phen
fenfluramine
givosiran
gw pharmaceuticals
hereditary transthyretin amyloidosis
inotersen
john berk
lennox-gastaut syndrome
mary o'donnell
national top stories
new york blog main
new york top stories
onpattro
paul matteis
regeneron pharmaceuticals
san diego blog main
What
ago
3
×
fda
medicine
3
×
alnylam
drug
pharmaceuticals
rna
weeks
approval
approve
approved
awaits
battle
biological
cannabis
crossed
data
decades
decision
derivative
discovered
epilepsy
fingers
form
friday
gw
gw’s
historic
indicated
interference
marijuana
market
nod
patients
quick
rare
rnai
second
seek
sets
Language
Current search:
ago
×
fda
×
medicine
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug
